ecancermedicalscience

Clinical Study

Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer

5 Jan 2021
Gabriela Candás, Alejandra García, María Delfina Ocampo, Ernesto Korbenfeld, H Daniel Vuoto, Juan Isetta, Lucas Cogorno, Agustina González Zimmermann, Marca Sigal, Santiago Acevedo, Julia Berwart, Martín Naveira, Agustina Bemi, Juan Luis Uriburu

Introduction: Currently, the indication for neoadjuvant chemotherapy is increasing in the treatment of breast cancer. Variability in the expression of biomarkers following neoadjuvant treatment has been observed, which could be accompanied by changes in the adjuvant treatment.

Objectives: The primary objective was to evaluate the variability of biomarkers prior to and following neoadjuvant therapy. Secondary objectives were to determine which tumour subtype (as determined by immunohistochemical markers) most frequently achieved pathological complete response (pCR); whether the biomarker variation resulted in a change in immunophenotype and subsequently modification to the adjuvant treatment.

Materials and methods: A retrospective observational analysis was carried out on patients with a diagnosis of breast cancer who had neoadjuvant therapy prior to surgery in the Breast Care Service of the Buenos Aires British Hospital between January 2009 and June 2020.

Results: One hundred and seventy-two patients were included. The pCR rate was 28.5%. The tumour immunophenotype that achieved pCR most frequently was the hormone receptor negative /HER2 group with a value of 85.2%. The analysis was carried out on the 123 patients with residual disease. The observed variability for oestrogen receptors (ER) was 8.9%, for progesterone receptors (PR), 29.9% and for HER2, 13.8%. These changes were statistically significant. There were changes to the tumour immunophenotype in 26 cases (21.1%) with modifications to the adjuvant treatment in nine of these (34.6%; 7.3% of all tumours with residual disease).

Conclusions: In this study, we observed statistically significant variability in the expression of ER, PR and HER2 prior to and following neoadjuvant treatment, which identified modifications in the tumour immunophenotype in 21.1%, and changes to the adjuvant treatment in 7.3% of all tumours with residual disease, justifying the re-assay of biomarkers in the surgical specimen.

Related Articles

Eduardo Payet, Joan Perez, Gustavo Sarria, Silvia Neciosup, Francisco Berrospi, Sheila Vilchez, Jorge Dunstan, Ronald Perez, Mauricio Vassallo, Santiago Salgado, Nanto Caparachín, Joseph A Pinto, Alexis Holguin
Namrata Mathew, Anjana Joel, Anand George Andrews, Ajoy Oommen John, Ashish Singh
Tomás Reinert, Alessandra Borba Anton de Souza, Guilherme Parisotto Sartori, Fernando Mariano Obst, Carlos Henrique Barrios
Groesbeck Preer Parham, Kabongo Mukuta Mathieu, Tankoy Gombo YouYou, Michael L Hicks, Ronda Henry-Tillman, Alex Mutombo, Mukanya Mpalata Anaclet, Mulumba Kapuku Sylvain, Leeya Pinder, Maya M Hicks, Louis Kanda, Mirielle Kanda
Kabongo Mukuta Mathieu, Tankoy Gombo YouYou, Michael L Hicks, Alex Mutombo, Mukanya Mpalata Anaclet, Mulumba Kapuku Sylvain, Leeya Pinder, Maya M Hicks, Louis Kanda, Mirielle Kanda, Groesbeck P Parham, Ronda Henry-Tillman